Arcturus Therapeutics Holdings Inc. (ARCT) NASDAQ
$26.98 (0.95) (-3.40%)
Market Cap: $751.74M
As of 04/24/24 04:00 PM EDT. Market closed.
Arcturus Therapeutics Holdings Inc. (ARCT)
NASDAQ
$26.98
(0.95) (-3.40%)
Market Cap: $751.74M
As of 04/24/24 04:00 PM EDT. Market closed.
Add to Portfolio
founded in 2013 and based in san diego, calif., arcturus therapeutics is poised to become an industry leader in the application of rnai technologies for the treatment of disease and improved quality of life. the company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. backed by a management team with extensive ... read more
COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Full Time Employees
184
Address
.
PRICE CHART FOR ARCTURUS THERAPEUTICS HOLDINGS INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$28.25
Previous Close
$27.93
Days Range
$27.03 - $28.78
52 week range
$17.52 - $43.81
Volume
266,354
Avg. Volume (30 days)
523,479
Market Cap
$751.74M
Dividend Yield
-
P/E
(25.29)
Shares Outstanding
26,915,243
Open
$28.25
Previous Close
$27.93
Days Range
$27.03 - $28.78
52 week range
$17.52 - $43.81
Volume
266,354
Avg. Volume (30 days)
523,479
Market Cap
$751.74M
Dividend Yield
-
P/E
(25.29)
Shares Outstanding
26,915,243
FINANCIAL STATEMENTS FOR ARCTURUS THERAPEUTICS HOLDINGS INC
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR ARCTURUS THERAPEUTICS HOLDINGS INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Chivukula Pad | Chief Scientific Officer & COO | Mar 25, 2024 | Sale | $35.02 | 17,435 | 610,574 | 473,448 | Mar 27, 2024, 04:15 PM |
| Chivukula Pad | Chief Scientific Officer & COO | Mar 19, 2024 | Sale | $35.01 | 8,565 | 299,839 | 490,883 | Mar 21, 2024, 05:27 PM |
| Chivukula Pad | Chief Scientific Officer & COO | Nov 01, 2023 | Sale | $18.72 | 5,000 | 93,602 | 499,448 | Nov 03, 2023, 04:30 PM |
| Chivukula Pad | Chief Scientific Officer & COO | Oct 02, 2023 | Sale | $25.61 | 5,000 | 128,062 | 504,448 | Oct 04, 2023, 04:06 PM |
| Chivukula Pad | Chief Scientific Officer & COO | Sep 01, 2023 | Sale | $31.45 | 5,000 | 157,263 | 509,448 | Sep 05, 2023, 04:05 PM |
| SASSINE ANDY | Chief Financial Officer | Aug 15, 2023 | Option Exercise | $17.37 | 1,223 | 21,248 | 270,526 | Aug 17, 2023, 05:00 PM |
| Chivukula Pad | Chief Scientific Officer & COO | Aug 01, 2023 | Sale | $34.91 | 5,000 | 174,550 | 514,448 | Aug 03, 2023, 04:15 PM |
| Chivukula Pad | Chief Scientific Officer & COO | Jul 14, 2023 | Sale | $35.01 | 25,000 | 875,250 | 519,448 | Jul 18, 2023, 06:50 PM |
| Kummerfeld Keith C | See Remarks | Jul 14, 2023 | Option Exercise | $8.96 | 6,968 | 62,408 | 7,918 | Jul 18, 2023, 06:50 PM |
| Kummerfeld Keith C | See Remarks | Jul 14, 2023 | Sale | $35.00 | 6,968 | 243,880 | 950 | Jul 18, 2023, 06:50 PM |
| Chivukula Pad | Chief Scientific Officer & COO | Jul 03, 2023 | Sale | $28.75 | 5,000 | 143,750 | 544,448 | Jul 07, 2023, 06:01 AM |
| Chivukula Pad | Chief Scientific Officer & COO | Jun 01, 2023 | Sale | $27.16 | 5,000 | 135,800 | 549,448 | Jun 05, 2023, 04:07 PM |
| Chivukula Pad | Chief Scientific Officer & COO | May 11, 2023 | Sale | $30.24 | 7,925 | 239,652 | 554,448 | May 12, 2023, 04:05 PM |
| Chivukula Pad | Chief Scientific Officer & COO | May 10, 2023 | Sale | $30.00 | 17,075 | 512,250 | 562,373 | May 12, 2023, 04:05 PM |
| Chivukula Pad | Chief Scientific Officer & COO | May 01, 2023 | Sale | $25.93 | 5,000 | 129,650 | 579,448 | May 03, 2023, 04:08 PM |
| Kummerfeld Keith C | See Remarks | Apr 18, 2023 | Option Exercise | $8.96 | 6,968 | 62,408 | 7,918 | Apr 19, 2023, 04:57 PM |
| Kummerfeld Keith C | See Remarks | Apr 18, 2023 | Sale | $28.18 | 6,968 | 196,358 | 950 | Apr 19, 2023, 04:57 PM |
| Chivukula Pad | Chief Scientific Officer & COO | Apr 03, 2023 | Sale | $25.38 | 5,000 | 126,900 | 584,448 | Apr 05, 2023, 08:47 PM |
| Chivukula Pad | Chief Scientific Officer & COO | Mar 06, 2023 | Sale | $16.07 | 5,000 | 80,350 | 589,448 | Mar 08, 2023, 09:34 PM |
| Marquet Magda | Director | Dec 15, 2022 | Buy | $18.00 | 2,222 | 39,996 | 24,942 | Dec 19, 2022, 05:02 PM |
| Payne Joseph E | President and CEO | Nov 23, 2022 | Buy | $16.51 | 5,000 | 82,550 | 1,480,097 | Nov 28, 2022, 04:07 PM |
| SASSINE ANDY | Chief Financial Officer | Aug 15, 2022 | Option Exercise | $18.42 | 1,068 | 19,672 | 269,303 | Aug 17, 2022, 04:05 PM |
| Chivukula Pad | Chief Scientific Officer & COO | Jan 04, 2022 | Sale | $40.00 | 8,100 | 324,000 | 594,448 | Jan 06, 2022, 04:01 PM |
| Chivukula Pad | Chief Scientific Officer & COO | Dec 16, 2021 | Sale | $40.00 | 3,633 | 145,328 | 602,548 | Dec 20, 2021, 04:01 PM |
| Chivukula Pad | Chief Scientific Officer & COO | Dec 08, 2021 | Sale | $40.00 | 6,367 | 254,680 | 606,181 | Dec 10, 2021, 04:01 PM |
| Chivukula Pad | Chief Scientific Officer & COO | Nov 01, 2021 | Sale | $44.41 | 10,000 | 444,100 | 612,548 | Nov 03, 2021, 11:20 AM |
| Chivukula Pad | Chief Scientific Officer & COO | Oct 01, 2021 | Sale | $44.36 | 10,000 | 443,600 | 622,548 | Oct 04, 2021, 05:01 PM |
| Chivukula Pad | Chief Scientific Officer & COO | Sep 01, 2021 | Sale | $55.86 | 10,000 | 558,600 | 632,548 | Sep 02, 2021, 09:06 PM |
| Ultragenyx Pharmaceutical Inc. | Director | Aug 11, 2021 | Sale | $45.83 | 75,000 | 3,437,250 | 1,400,000 | Aug 12, 2021, 05:11 PM |
| Ultragenyx Pharmaceutical Inc. | Director | Aug 10, 2021 | Sale | $55.44 | 725,000 | 40,193,999 | 1,475,000 | Aug 12, 2021, 05:11 PM |
| Chivukula Pad | Chief Scientific Officer & COO | Aug 03, 2021 | Sale | $40.07 | 10,000 | 400,700 | 642,548 | Aug 05, 2021, 04:32 PM |
| Chivukula Pad | Chief Scientific Officer & COO | Mar 01, 2021 | Sale | $54.23 | 10,000 | 542,300 | 662,548 | Mar 03, 2021, 04:30 PM |
| Chivukula Pad | Chief Scientific Officer & COO | Feb 01, 2021 | Sale | $75.31 | 10,000 | 753,100 | 672,548 | Feb 03, 2021, 04:45 PM |
| Chivukula Pad | Chief Scientific Officer & COO | Jan 04, 2021 | Sale | $46.40 | 10,000 | 464,000 | 682,548 | Jan 05, 2021, 06:19 PM |
| Ultragenyx Pharmaceutical Inc. | Director | Dec 09, 2020 | Sale | $94.97 | 357,745 | 33,975,043 | 2,200,000 | Dec 10, 2020, 04:55 PM |
| Ultragenyx Pharmaceutical Inc. | Director | Dec 08, 2020 | Sale | $105.54 | 442,255 | 46,675,593 | 2,557,745 | Dec 10, 2020, 04:55 PM |
| Chivukula Pad | Chief Scientific Officer & COO | Dec 01, 2020 | Sale | $96.19 | 10,000 | 961,900 | 692,548 | Dec 03, 2020, 05:45 PM |
| Chivukula Pad | Chief Scientific Officer & COO | Nov 02, 2020 | Sale | $55.28 | 10,000 | 552,800 | 702,548 | Nov 03, 2020, 08:01 PM |
| Chivukula Pad | Chief Scientific Officer & COO | Oct 01, 2020 | Sale | $42.83 | 10,000 | 428,300 | 712,548 | Oct 02, 2020, 05:00 PM |
| Chivukula Pad | Chief Scientific Officer & COO | Sep 03, 2020 | Sale | $45.16 | 10,000 | 451,600 | 722,548 | Sep 04, 2020, 05:05 PM |
| Kummerfeld Keith C | See Remarks | Jun 12, 2020 | Buy | $33.33 | 450 | 14,999 | 950 | Jun 12, 2020, 06:22 PM |
| Payne Joseph E | President and CEO | Jun 10, 2020 | Buy | $31.69 | 1,000 | 31,690 | 1,475,097 | Jun 10, 2020, 09:59 PM |
| SASSINE ANDY | Chief Financial Officer | Jun 10, 2020 | Buy | $29.74 | 5,000 | 148,700 | 273,245 | Jun 10, 2020, 09:59 PM |
| Ultragenyx Pharmaceutical Inc. | Director | May 20, 2020 | Option Exercise | $16.00 | 600,000 | 9,600,000 | 3,000,000 | May 22, 2020, 01:41 PM |
| SASSINE ANDY | Chief Financial Officer | Dec 05, 2019 | Buy | $9.73 | 5,649 | 54,965 | 268,245 | Dec 09, 2019, 09:45 PM |
| SASSINE ANDY | Chief Financial Officer | Dec 03, 2019 | Buy | $10.00 | 10,000 | 100,000 | 257,596 | Dec 05, 2019, 09:39 PM |
| Marquet Magda | Director | Sep 13, 2019 | Buy | $10.58 | 2,300 | 24,334 | 22,720 | Sep 17, 2019, 09:37 PM |
| Kummerfeld Keith C | See Remarks | Sep 12, 2019 | Buy | $10.69 | 500 | 5,347 | 500 | Sep 12, 2019, 09:00 PM |
| Payne Joseph E | President and CEO | Aug 29, 2019 | Buy | $11.22 | 5,000 | 56,100 | 1,474,097 | Aug 30, 2019, 05:00 PM |
| SASSINE ANDY | Chief Financial Officer | Aug 23, 2019 | Buy | $10.90 | 10,000 | 109,000 | 247,596 | Aug 26, 2019, 07:00 AM |
| FARRELL PETER C | Director | Aug 20, 2019 | Buy | $10.85 | 4,432 | 48,087 | 42,955 | Aug 21, 2019, 07:51 PM |
| FARRELL PETER C | Director | Aug 19, 2019 | Buy | $11.02 | 4,681 | 51,585 | 38,523 | Aug 21, 2019, 07:51 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Chivukula Pad | Chief Scientific Officer & COO | 03/25/2024 | 610,574 |
| Chivukula Pad | Chief Scientific Officer & COO | 03/19/2024 | 299,839 |
| Chivukula Pad | Chief Scientific Officer & COO | 11/01/2023 | 93,602 |
| Chivukula Pad | Chief Scientific Officer & COO | 10/02/2023 | 128,062 |
| Chivukula Pad | Chief Scientific Officer & COO | 09/01/2023 | 157,263 |
| SASSINE ANDY | Chief Financial Officer | 08/15/2023 | 21,248 |
| Chivukula Pad | Chief Scientific Officer & COO | 08/01/2023 | 174,550 |
| Chivukula Pad | Chief Scientific Officer & COO | 07/14/2023 | 875,250 |
| Kummerfeld Keith C | See Remarks | 07/14/2023 | 62,408 |
| Kummerfeld Keith C | See Remarks | 07/14/2023 | 243,880 |
| Chivukula Pad | Chief Scientific Officer & COO | 07/03/2023 | 143,750 |
| Chivukula Pad | Chief Scientific Officer & COO | 06/01/2023 | 135,800 |
| Chivukula Pad | Chief Scientific Officer & COO | 05/11/2023 | 239,652 |
| Chivukula Pad | Chief Scientific Officer & COO | 05/10/2023 | 512,250 |
| Chivukula Pad | Chief Scientific Officer & COO | 05/01/2023 | 129,650 |
| Kummerfeld Keith C | See Remarks | 04/18/2023 | 62,408 |
| Kummerfeld Keith C | See Remarks | 04/18/2023 | 196,358 |
| Chivukula Pad | Chief Scientific Officer & COO | 04/03/2023 | 126,900 |
| Chivukula Pad | Chief Scientific Officer & COO | 03/06/2023 | 80,350 |
| Marquet Magda | Director | 12/15/2022 | 39,996 |
| Payne Joseph E | President and CEO | 11/23/2022 | 82,550 |
| SASSINE ANDY | Chief Financial Officer | 08/15/2022 | 19,672 |
| Chivukula Pad | Chief Scientific Officer & COO | 01/04/2022 | 324,000 |
| Chivukula Pad | Chief Scientific Officer & COO | 12/16/2021 | 145,328 |
| Chivukula Pad | Chief Scientific Officer & COO | 12/08/2021 | 254,680 |
| Chivukula Pad | Chief Scientific Officer & COO | 11/01/2021 | 444,100 |
| Chivukula Pad | Chief Scientific Officer & COO | 10/01/2021 | 443,600 |
| Chivukula Pad | Chief Scientific Officer & COO | 09/01/2021 | 558,600 |
| Ultragenyx Pharmaceutical Inc. | Director | 08/11/2021 | 3,437,250 |
| Ultragenyx Pharmaceutical Inc. | Director | 08/10/2021 | 40,193,999 |
| Chivukula Pad | Chief Scientific Officer & COO | 08/03/2021 | 400,700 |
| Chivukula Pad | Chief Scientific Officer & COO | 03/01/2021 | 542,300 |
| Chivukula Pad | Chief Scientific Officer & COO | 02/01/2021 | 753,100 |
| Chivukula Pad | Chief Scientific Officer & COO | 01/04/2021 | 464,000 |
| Ultragenyx Pharmaceutical Inc. | Director | 12/09/2020 | 33,975,043 |
| Ultragenyx Pharmaceutical Inc. | Director | 12/08/2020 | 46,675,593 |
| Chivukula Pad | Chief Scientific Officer & COO | 12/01/2020 | 961,900 |
| Chivukula Pad | Chief Scientific Officer & COO | 11/02/2020 | 552,800 |
| Chivukula Pad | Chief Scientific Officer & COO | 10/01/2020 | 428,300 |
| Chivukula Pad | Chief Scientific Officer & COO | 09/03/2020 | 451,600 |
| Kummerfeld Keith C | See Remarks | 06/12/2020 | 14,999 |
| Payne Joseph E | President and CEO | 06/10/2020 | 31,690 |
| SASSINE ANDY | Chief Financial Officer | 06/10/2020 | 148,700 |
| Ultragenyx Pharmaceutical Inc. | Director | 05/20/2020 | 9,600,000 |
| SASSINE ANDY | Chief Financial Officer | 12/05/2019 | 54,965 |
| SASSINE ANDY | Chief Financial Officer | 12/03/2019 | 100,000 |
| Marquet Magda | Director | 09/13/2019 | 24,334 |
| Kummerfeld Keith C | See Remarks | 09/12/2019 | 5,347 |
| Payne Joseph E | President and CEO | 08/29/2019 | 56,100 |
| SASSINE ANDY | Chief Financial Officer | 08/23/2019 | 109,000 |
| FARRELL PETER C | Director | 08/20/2019 | 48,087 |
| FARRELL PETER C | Director | 08/19/2019 | 51,585 |
Load More Insider Transactions
FUNDS WITH A POSITION IN ARCTURUS THERAPEUTICS HOLDINGS INC
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| BlackRock Inc. | 2,743,002 | 0.00236% | 14.37% | Other |
| ARK INVESTMENT MANAGEMENT LLC | 1,689,649 | 0.4% | -17.48% | Growth |
| GEODE CAPITAL MANAGEMENT, LLC | 538,265 | 0.00178% | 5.1% | Other |
| AQR CAPITAL MANAGEMENT LLC | 159,873 | 0.00949% | -7.16% | Other |
| ROYCE & ASSOCIATES LP | 129,836 | 0.04% | No change | Value |
| D. E. SHAW & CO., INC. | 73,795 | 0.00203% | 65.35% | Other |
| ALPS ADVISORS INC | 28,220 | 0.007% | -6.94% | Other |
| RENAISSANCE TECHNOLOGIES LLC | 10,202 | 0.0005% | -94.32% | Other |
CHANGE IN SHARES OUTSTANDING FOR ARCTURUS THERAPEUTICS HOLDINGS INC
STOCK BUYBACKS FOR ARCTURUS THERAPEUTICS HOLDINGS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
0.98%
1Q
06/30/2023
1.02%
2Q
03/31/2023
-1.16%
3Q
12/31/2022
-7.79%
4Q
09/30/2022
1.39%
5Q
06/30/2022
1.55%
6Q
03/31/2022
1.74%
7Q
12/31/2021
1.79%
8Q
09/30/2021
1.89%
9Q
06/30/2021
1.95%
10Q
03/31/2021
2.26%
11Q
12/31/2020
32.16%
12Q
09/30/2020
16.99%
13Q
06/30/2020
42.78%
14Q
03/31/2020
84.80%
15Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR ARCTURUS THERAPEUTICS HOLDINGS INC
LOADING...